Objectives: We sought to determine the impact of timing of appropriate antifungal therapy, as assessed by susceptibility results, on patient survival.
Introduction
Candida is the fourth most common causative pathogen of nosocomial bloodstream infection (BSI) after coagulasenegative staphylococci, Staphylococcus aureus and Enterococcus species, 1 and invasive candidiasis is associated with high mortality. 2 -4 Furthermore, invasive fungal infections are responsible for an increasing proportion of infection-related deaths in the USA. 5 Timely therapy of BSI is of critical importance and inadequate initial therapy adversely impacts hospital mortality. 6, 7 Furthermore, fungal BSIs are associated with higher rates of inadequate initial antimicrobial treatment than bacterial BSIs 6 and carry high mortality rates. 2 -4 The importance of early treatment of candidaemia has been suggested by some investigators. 8, 9 However, there are limited data definitively demonstrating that early therapy for candidaemia benefits patients. The results of studies addressing this question are conflicting 8 -17 and most of these studies have not employed in vitro antifungal susceptibility results to assess the appropriateness of therapy. 8 -11,15 -17 The purpose of the present study is to investigate the impact of the timing of appropriate antifungal therapy, as assessed by antifungal drug susceptibility results, on mortality among patients with Candida BSI.
Methods
This study was conducted at an urban academic medical centre with 489 beds, including 52 adult critical care beds, active abdominal solid organ and stem cell transplant programmes, and a cancer centre. All patients ≥16 years of age with Candida bloodstream infection (Candida BSI) from January 2001 to December 2009 were identified by the Clinical Microbiology Laboratory. Only the first episode of candidaemia was included for patients with multiple episodes during the study period. Data collection was performed retrospectively to obtain the following information: demographics; comorbidities; severity of illness based on Acute Physiology and Chronic Health Evaluation (APACHE) II scores (the most aberrant values within 24 h prior to the collection of blood samples indicating candidaemia were obtained); presence of mechanical ventilation; time of collection of the first positive blood culture for Candida; time of initiation of first appropriate antifungal therapy; initial and follow-up blood culture results; microbiological response to antifungal therapy; and mortality. The difference between the time of collection of the first positive blood culture for Candida and receipt of the first appropriate antifungal therapy was defined as the time to appropriate antifungal therapy. Data on the receipt of corticosteroids were collected and the use of high-dose steroids was defined as ≥15 mg prednisone equivalents daily. Patients who received appropriate antifungal therapy for ≥24 h prior to initial BSI culture were excluded from the analysis. The receipt of inappropriate antifungal therapy for ≥24 h prior to the initial BSI culture was not a criterion for study exclusion. Blood cultures were ordered at the discretion of the primary medical team, based on the presence of signs and/or symptoms of BSI. Blood samples were obtained by nursing or phlebotomy personnel following skin and/or catheter sterilization. Blood samples were inoculated into one aerobic and one anaerobic bottle, and processed using the BacT/ ALERT w 3D (bioMérieux, Inc., Durham, NC, USA) automated microbial detection system. Organism identification was made using the Vitek w 2 Yeast Biochemical Card (bioMérieux, Inc.). The API w 20C AUX Yeast Identification Kit (bioMérieux, Inc.) was utilized for organisms that failed identification by the primary method. The appropriateness of antifungal therapy was based on antifungal susceptibility testing, which became routine at our institution for fluconazole, itraconazole and flucytosine in 2003, for voriconazole, posaconazole and amphotericin B in 2007, and for the echinocandins in 2008. Antifungal susceptibilities were determined with the Sensititre w YeastOne w panel (Trek Diagnostic Systems, Inc., Cleveland, OH, USA). For fluconazole-susceptible Candida isolates (MIC ≤8 mg/L), a minimum daily dose of 400 mg was considered appropriate. For fluconazole-susceptible dose-dependent (SDD; MIC 16-32 mg/L) isolates, a minimum daily dose of 800 mg was considered appropriate. 18 For patients with a calculated creatinine clearance 19 ,50 mL/min, a daily dose of fluconazole of 50% of the normal dose was considered appropriate based on standard dosing adjustments made in renal dysfunction.
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The appropriateness of dosing of other antifungals was defined as follows:
21 ≥0.5 mg/kg of amphotericin B deoxycholate once daily; ≥3 mg/kg of lipid formulations of amphotericin B once daily; 70 mg of caspofungin (formulary echinocandin through March 2008) ×1 dose followed by 50 mg once daily (or 35 mg once daily for patients with significant liver impairment); 100 mg of micafungin (formulary echinocandin beginning April 2008) once daily; and 6 mg/kg of voriconazole twice daily ×2 doses followed by ≥3 mg/kg twice daily. In the absence of antifungal susceptibility testing, the following criteria were used to assess the appropriateness of therapy: 400 mg of fluconazole daily was deemed appropriate for the treatment of BSI caused by Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae; ≥800 mg of fluconazole daily was defined as appropriate for the treatment of Candida glabrata; amphotericin B was considered inappropriate for the treatment of BSI caused by C. lusitaniae; fluconazole was considered inappropriate for the treatment of Candida krusei; the echinocandins were assessed as appropriate for the treatment of all Candida species; voriconazole and posaconazole were considered appropriate for all non-glabrata Candida species; and patients receiving voriconazole or posaconazole for C. glabrata infection in the absence of antifungal susceptibility testing were excluded from analysis ( Table 1) .
Microbiological response was defined as culture-confirmed resolution of infection within 7 days of initiation of appropriate antifungal therapy sustained for ≥6 weeks after the original culture date. Persistent Candida BSI was defined as .7 days of candidaemia caused by the initial organism(s) after initiation of appropriate antifungal therapy. Microbiological failure was defined as persistent, recurrent or new BSI due to Candida within 6 weeks of the first positive culture. Patients were followed for outcomes after onset of Candida BSI. The time to death or loss to follow-up within 30 days after infection was recorded.
The x 2 test was performed to assess for differences in 30 day mortality based on receipt and timing of appropriate antifungal therapy. A Kaplan-Meier curve was constructed to illustrate the relationship Grim et al.
between the receipt and timing of appropriate antifungal therapy on survival; the log-rank test was used to assess for statistical differences between groups. Univariable Cox regression was performed to determine the patient and infection characteristics associated with 30 day survival.
The proportional hazards assumption was tested graphically and with the creation of time-dependent variables. Clinically plausible variables with a P value of ≤0.2 were entered into a multivariable Cox regression model. Statistical analyses were performed with PASW Statistics v. 17.0 (SPSS, Chicago, IL, USA). Institutional review board approval was obtained.
Results
There were 453 patients with first episodes of Candida BSI during the study period. Six patients received ≥24 h of appropriate antifungal therapy prior to first Candida BSI culture and were excluded. One additional patient was excluded because the appropriateness of antifungal therapy could not be determined based on a priori definitions; the patient received voriconazole for C. glabrata BSI without voriconazole susceptibility testing. The study sample therefore included 446 patients with a mean age of 53 years; 243 (54%) were female and 229 (51%) were black ( Table 2 ). The number of first episodes of Candida BSI averaged 49 per year; there were no discernible trends in the number of infections per year. The most common comorbidities were diabetes mellitus (131, 29%), solid tumour (120, 27%) and cirrhosis (72, 16%), and 249 (56%) of patients were in the intensive care unit (ICU) at the time of Candida BSI. The mean and median APACHE II scores were 18.9 and 17.0, respectively. C. albicans was the most common pathogen (221, 50%), followed by C. glabrata (99, 22%), C. parapsilosis (59, 13%), C. tropicalis (48, 11%) and C. krusei (6, 1%). Antifungal susceptibilities were reported for 380/446 (85%) patients. Appropriate antifungal therapy consisted of fluconazole (177, 40%), caspofungin or micafungin (125, 28%), amphotericin B (41, 9%) and voriconazole (6, 1%). A relatively high percentage of patients (97, 22%) did not receive appropriate initial antifungal therapy; 55 patients (12%) failed to receive any antifungal therapy and 42 patients (9%) received insufficient doses of fluconazole (21 received ,400 mg/day for a fluconazole-susceptible isolate, 11 received ,800 mg/day for a fluconazole-SDD isolate, 3 received ,800 mg for C. glabrata without susceptibilities, 5 received fluconazole for a fluconazole-resistant isolate and 2 received fluconazole for BSI caused by C. krusei; Table 1 ).
The 30 day mortality was compared based on the time to initiation of appropriate antifungal therapy (Figure 1 ). The overall mortality was 34% (151/446), with the highest mortality (45%, 44/97) among the 97 patients who failed to receive appropriate antifungal therapy (data not shown). Though still considerable, mortality was significantly lower for those who received appropriate antifungal therapy ( 30%). There was a slight trend toward lower 30 day mortality for patients who received appropriate antifungal therapy within 72 h of the collection of a positive blood culture, but the difference was not statistically significant (32% versus 36%, P ¼ 0.11). We also analysed the survival of the two groups over time according to the timing of appropriate antifungal therapy. A Kaplan -Meier 30 day survival curve for these data is illustrated in Figure 2 (a). There was no significant difference in survival between the patients who received appropriate antifungal therapy within 72 h or beyond 72 h from the initial positive culture being drawn (P¼ 0.18), but again there was a trend toward lower survival over time among the latter group.
Univariable Cox regression analysis (Table 3 ) of all patients with Candida BSI (n ¼446) demonstrated that a number of variables were associated with increased mortality risk, including increased age, immunosuppression (e.g. HIV infection, cirrhosis and high-dose steroid therapy), critical illness (e.g. ICU residence at the time of Candida BSI, mechanical ventilation, renal dysfunction and increased APACHE II score) and pathogen factors (e.g. BSI caused by C. glabrata and BSI caused by a fluconazole-non-susceptible isolate). Microbiological response to treatment could not be assessed in 89 patients, but of the remaining 357 patients, 51 (14%) had microbiological failure (22 persistent and 29 new or recurrent BSI). Notably, the microbiological clearance of infection was protective against mortality. The receipt of appropriate antifungal therapy .72 h after the collection of a positive blood culture was associated with a hazard ratio (HR) of 1.24 (95% CI 0.90-1.71, P¼0.19). On multivariable Cox regression analysis (Table 4) , an increased APACHE II score (HR 1.11, 95% CI 1.09-1.13, P,0.001), cirrhosis (HR 2.15, 95% CI 1.48-3.13, P,0.001) and HIV infection (HR 2.03, 95% CI 1.11-3.72, P¼0.02) were independent predictors of mortality controlling for age, serum creatinine ≥2.0 mg/dL and receipt of appropriate antifungal therapy .72 h after collection of a positive blood culture. When controlling for these other clinical characteristics, the timing of appropriate antifungal therapy was not associated with survival after Candida BSI. There was also no association between timing of appropriate antifungal therapy and microbiological resolution of Candida BSI, including persistent infection.
Because it was possible that patients who died before receiving 24 h of appropriate antifungal therapy may not have benefitted from this therapy even if treatment was administered in a timely manner, a secondary analysis was performed to account for this possibility. There were 18 patients who died prior to receiving 24 h of appropriate antifungal therapy, 14 of whom received appropriate therapy within 72 h of collection of first positive blood culture. These 14 patients were therefore reclassified as having not received timely appropriate therapy given the short duration of antifungal treatment before death (i.e. they were reclassified in the .72 h group). In this analysis, the 30 day mortality was significantly lower among patients who received appropriate antifungal therapy within 72 h of a positive culture being drawn (27% versus 40%, P ¼0.004) and the Kaplan -Meier curve revealed a significant difference in survival between the two groups (Figure 2b ; P ¼ 0.001). In addition, on univariable (HR 1.75, 95% CI 1.26 -2.43, P ¼ 0.001) and multivariable (HR 1.41, 95% CI 1.01 -1.98, P ¼ 0.045) analyses, delayed receipt of antifungals was associated with decreased survival. An analysis was also performed excluding the 18 patients who died before receiving 24 h of appropriate antifungal therapy and the 30 day mortality remained significantly lower among patients who received appropriate antifungal therapy within 72 h of a positive culture being drawn (28% versus 37%, P ¼ 0.047).
Discussion
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therapy for survival after Candida BSI and one of only four similar studies 12 -14 incorporating in vitro susceptibility results to assess the appropriateness of therapy. In our primary analysis, we could not demonstrate a significant association between the receipt of early appropriate antifungal therapy and outcomes, including mortality, microbiological response and persistent infection. However, we also took into account the fact that some patients, although they received antifungal treatment in a timely manner, may not have had an adequate duration of treatment to affect outcome. When we reclassified or excluded patients who died very soon after receiving appropriate therapy, we did find a significant mortality benefit to initiating antifungal therapy within 72 h of obtaining a positive blood culture.
Our results differ in some respects from those of previous investigators. In 2005 and 2006 , two studies demonstrated a clear relationship between delaying the initiation of antifungal therapy and mortality. The first of these by Morrell et al. 8 concluded that in a retrospective analysis of 157 candidaemic patients, the administration of antifungal treatment ≥12 h after the collection of the first blood culture positive for Candida was an independent risk factor for hospital mortality (adjusted odds ratio 2.09, 95% CI 1.53-2.84, P¼0.018). A major limitation of this study was that only nine patients received antifungal treatment within 12 h of having a blood culture positive for Candida obtained, limiting the ability to draw firm conclusions regarding the results due to the small sample size. The mortality rates for patients who received therapy at 12-24, 24-48 and .48 h after a positive blood culture were similar and were in the range of overall mortality of our study (32% versus 34%, respectively). Furthermore, routine antifungal susceptibility testing was not performed on Candida isolates and, thus, the appropriateness of therapy could not be assessed.
A second retrospective cohort study examined the mortality associated with the timing of fluconazole therapy in 230 patients with candidaemia at four medical centres. 9 Mortality rates were lowest for patients beginning fluconazole on the day the first positive blood culture was drawn and rates rose progressively with time to initiation of fluconazole. Earlier initiation of fluconazole was also associated with a decreased length of ICU stay. An important limitation of this study, as in that by Morrell et al., 8 is the lack of antifungal susceptibility testing to assess the appropriateness of therapy. In addition, the study did not examine the effects of newer antifungal agents that are being increasingly used for invasive Candida infections. 21 The results of subsequent studies on this topic have yielded conflicting results. Two smaller studies 15, 17 have supported the conclusions of Morrell et al. 8 and Garey et al. 9 Patel et al.
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described increased mortality among 31 patients with Candida-associated septic shock when appropriate antifungal therapy was not received within 15 h of blood sample collection. studied 90 patients with candidaemia requiring ICU admission. Eighty out of 90 patients failed to received appropriate antifungal therapy within 24 h of infection; in this group the hospital mortality rate was 29% compared with 0% among the 10 patients who received early appropriate therapy (P ¼ 0.059). Both studies were limited by the lack of availability of routine antifungal susceptibility testing. Several more recent studies have failed to find an association between the timely receipt of antifungal therapy and mortality after Candida BSI. 10 -14,16 Taur et al. 16 studied 106 patients with cancer and Candida BSI, and reported that a longer period Grim et al.
from the time a positive blood culture was drawn until it became positive ('incubation time') was independently associated with an increased risk of hospital mortality on multivariable analysis. However, the total length of time from when a positive blood culture was drawn to the time of antifungal initiation did not independently affect outcome. From a sample of 96 patients without antifungal susceptibility testing, Fernandez et al.
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reported no difference in the time to antifungal therapy among survivors (61 h) versus non-survivors (59 h) of Candida BSI. Hsu et al. 11 investigated patients who received an echinocandin for Candida BSI; early (≤3 days, n¼ 107) versus late (.3 days, n¼ 62) initiation of caspofungin for candidaemia was associated with an improved overall response (77% versus 57%, P ¼0.006), but it was not associated with infection-related or all-cause hospital mortality. Parkins et al.
14 analysed 199 patients with invasive candidiasis and although appropriate empirical antifungal therapy was protective against hospital mortality, there was no association between timing of antifungal administration and mortality. In this study, antifungal susceptibility testing was available for 89% of the study participants. Klevay et al. 12 and Kludze-Forson et al. 13 reported antifungal susceptibilities for 100% of their study patients. Klevay et al. 12 conducted a matched study of patients with BSI caused by C. albicans (n¼ 54) or C. glabrata (n¼ 54), and found that patients with C. glabrata were not less likely to receive appropriate antifungal therapy and that there was no association between timing of therapy and 30 day mortality. Similarly, Kludze-Forson et al. 13 reported the absence of an association between the timing of appropriate antifungal therapy and hospital mortality among 123 candidaemic patients; increased severity of illness score was the only independent predictor of mortality.
The reason for differing results among various studies investigating the impact of timing of antifungal therapy on outcomes is unknown, but multiple complex factors are likely responsible. Study design details, such as the size of study populations and subgroups, differences in patient comorbidities and illness severity, and variations in the antifungal drugs studied, may have affected the ability to discern the true effect of appropriate early antifungal therapy. With the exception of the study by Patel et al., 15 our study population had the highest mean APACHE II scores. It is possible that results obtained in the studies by Morrell et al. 8 and Garey et al. 9 may not be as applicable to a more critically ill population of patients. Importantly, we obtained different findings when reclassifying the small subgroup of patients who died before receiving 24 h of effective antifungal therapy as having never received appropriate therapy; in this analysis, the 30 day mortality and survival results are more consistent with the original findings by Morrell et al. 8 and Garey et al., 9 showing an impact of earlier antifungal therapy on outcome. None of the previous studies assessing the timing of therapy in candidaemia has performed a similar analysis and this may be an important consideration in any future studies of this type. Lastly, the biggest difference may be the fact that many earlier studies did not employ the routine use of antifungal susceptibility testing to assess the appropriateness of therapy. In any case, it may be that patient comorbidities and critical illness, or pathogen factors, may be just as important if not more important in determining mortality than early administration of antifungal therapy.
The strengths of the current study are its size, use of antifungal susceptibility data, strict criteria for assessing the appropriateness of therapy and the inclusion of detailed information about study patients, including multiple severity-of-illness indicators. However, it is important to recognize that the retrospective design did not allow the capture of all possible data that could have been important in assessing outcomes, such as symptom onset. In addition, the study was conducted at a single centre and therefore may not be directly applicable to other institutions or settings. Lastly, it is assumed in the study design that blood cultures were drawn at the first suspicion of infection, but it is possible that the time to appropriate antifungal therapy was longer for some patients than was assessed if there was a delay in obtaining blood cultures in candidaemic patients. This type of bias could explain higher than expected mortality in patients who appeared to receive early appropriate antifungal therapy. Despite these limitations, our data are consistent with prior studies indicating a high mortality rate among hospitalized patients with candidaemia as well as a particularly high mortality rate among those who never receive appropriate antifungal therapy. Furthermore, we confirmed that BSI due to C. glabrata or fluconazole-non-susceptible Candida isolates are associated with a higher mortality, 22 -25 as are those BSI due to C. krusei where fluconazole therapy is administered. 22, 26 In conclusion, among a large group of patients with Candida BSI, we did not find a survival benefit to early appropriate antifungal therapy when analysing the study population as a whole, but noted that outcomes could be affected by whether patients had received a certain minimum duration of antifungal therapy. Our results are supported by the inclusion of routine antifungal susceptibility testing to optimally assess the appropriateness of treatments and the fact that the use of newer antifungal medications was included in the analysis. Given the high mortality seen in most studies of candidaemic patients, additional manoeuvres are needed to try to improve outcomes in these patients.
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